Search Within

Alexandra Elizabeth Snyder Charen

  1. "Epidemiology and Biostatistics"
Formats
  1. Journal Article (8)
  2. Meeting Abstract (1)
Groups
  1. Epidemiology and Biostatistics (9)
  2. Biostatistics Service (8)
  3. Department of Medicine (8)
  4. Solid Tumor Oncology Division (8)
  5. Gynecology Disease Management Team (7)
  6. Human Oncology and Pathogenesis Program (7)

More Groups

People
  1. Alexia Iasonos (4)
  2. David Hyman (4)
  3. Dmitriy Zamarin (4)
  4. Jason Konner (4)
  5. Margaret Callahan (4)
  6. Carol Aghajanian (3)

More People

Years
  1. 2020 (2)
  2. 2019 (2)
  3. 2018 (2)
  4. 2017 (2)
  5. 2015 (1)
Publications
  1. JCO Precision Oncology (2)
  2. Journal of Clinical Oncology (2)
  3. Cancer Cell (1)
  4. Cancer Chemotherapy and Pharmacology (1)
  5. Gynecologic Oncology (1)
  6. Journal for ImmunoTherapy of Cancer (1)

More Publications

Publishers
  1. American Society of Clinical Oncology (4)
  2. Biomed Central Ltd (1)
  3. Cell Press (1)
  4. Elsevier Inc. (1)
  5. Nature Publishing Group (1)
  6. Springer (1)

Results (9)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer
    Journal Article

    Friedman, C. F.; Snyder Charen, A.; Zhou, Q.; Carducci, M. A.; Buckley De Meritens, A.; Corr, B. R.; Fu, S.; Hollmann, T. J.; Iasonos, A.; Konner, J. A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy
    Journal Article

    Jiménez-Sánchez, A.; Cybulska, P.; LaVigne Mager, K.; Koplev, S.; Cast, O.; Couturier, D. L.; Memon, D.; Selenica, P.; Nikolovski, I.; Mazaheri, Y.; more...
    Nature Genetics (2020)

    Fulltext@MSK | Save
  • Radiogenomics analysis of intratumor heterogeneity in a patient with high-grade serous ovarian cancer
    Journal Article

    Weigelt, B.; Vargas, H. A.; Selenica, P.; Geyer, F. C.; Mazaheri, Y.; Blecua, P.; Conlon, N.; Hoang, L. N.; Jungbluth, A. A.; Snyder, A.; more...
    JCO Precision Oncology (2019)

    Fulltext@MSK | Save
  • Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
    Journal Article

    Boland, J. L.; Zhou, Q.; Martin, M.; Callahan, M. K.; Konner, J.; O'Cearbhaill, R. E.; Friedman, C. F.; Tew, W.; Makker, V.; Grisham, R. N.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers
    Journal Article

    Teo, M. Y.; Seier, K.; Ostrovnaya, I.; Regazzi, A. M.; Kania, B. E.; Moran, M. M.; Cipolla, C. K.; Bluth, M. J.; Chaim, J.; Al-Ahmadie, H.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Genomic features of response to combination immunotherapy in patients with advanced non-small-cell lung cancer
    Journal Article

    Hellmann, M. D.; Nathanson, T.; Rizvi, H.; Creelan, B. C.; Sanchez-Vega, F.; Ahuja, A.; Ni, A.; Novik, J. B.; Mangarin, L. M. B.; Abu-Akeel, M.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • OncoKB: A precision oncology knowledge base
    Journal Article

    Chakravarty, D.; Gao, J.; Phillips, S.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J. E.; Yaeger, R.; Soumerai, T.; Nissan, M. H.; more...
    JCO Precision Oncology (2017)

    Fulltext@MSK | Save
  • A phase II trial of enzalutamide in patients with androgen receptor positive (AR+) ovarian, primary peritoneal or fallopian tube cancer and one, two, or three prior therapies
    Meeting Abstract

    Grisham, R. N.; Giri, D. D.; Iasonos, A.; Zhou, Q.; Girshman, J.; McGrath, S. P.; O'Cearbhaill, R. E.; Sabbatini, P.; Tew, W. P.; Hyman, D. M.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors
    Journal Article

    Hyman, D. M.; Snyder, A. E.; Carvajal, R. D.; Gerecitano, J. F.; Voss, M. H.; Ho, A. L.; Konner, J.; Winkelmann, J. L.; Stasi, M. A.; Monson, K. R.; more...
    Cancer Chemotherapy and Pharmacology (2015)

    Fulltext@MSK | Save